FY22 results are in line with revised estimates. Management continues to intensify its focus on the growing, profitable and cash generative Point-of-Care and Life Sciences activities, where confidence in the latter opportunity is increasing. We make some modest changes to our forecasts to reflect further streamlining post-period end and point to the strong growth outlook from FY24 onwards. We believe this is being overly discounted by the market and view the shares as being in deep value territo ....

28 Mar 2023
FY22 in line – focus on core increasing

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY22 in line – focus on core increasing
EKF Diagnostics Holdings plc (EKF:LON) | 28.6 0.2 2.1% | Mkt Cap: 129.8m
- Published:
28 Mar 2023 -
Author:
Chris Glasper -
Pages:
3 -
FY22 results are in line with revised estimates. Management continues to intensify its focus on the growing, profitable and cash generative Point-of-Care and Life Sciences activities, where confidence in the latter opportunity is increasing. We make some modest changes to our forecasts to reflect further streamlining post-period end and point to the strong growth outlook from FY24 onwards. We believe this is being overly discounted by the market and view the shares as being in deep value territo ....